Cartesian Therapeutics Inc
WKN: A407YS / ISIN: US8162123025Selecta Biosciences, Inc nach der KE 2019
| eröffnet am: | 31.01.19 17:27 von: | centsucher |
| neuester Beitrag: | 15.10.24 08:15 von: | Fu Hu |
| Anzahl Beiträge: | 65 | |
| Leser gesamt: | 24663 | |
| davon Heute: | 9 | |
bewertet mit 1 Stern |
||
|
Seite:
1
|
||
Selecta Biosciences, Inc. Ein kurzer Steckbrief.
Ein weiterer Finanzierungspflegefall!
Gut, jetzt ist der Kurs unten und die Finanzierung soll zu 1,5$ pro Aktie durchgeführt werden.
Aktien out vor 22,434,212 shares, danach sollen 45,471,776 shares werden.
As of November 2, 2018 , the registrant had 22,434,212 shares of common stock
We are offering 20,000,000 shares of our common stock.
We have granted the underwriters an option for a period of 30 days to purchase up to an additional 3,000,000 shares of our common stock
42,471,776 shares (or 45,471,776 shares if the underwriters exercise in full their option to purchase additional shares)
Sprich eine MK bei 1,5$ um cash!
As of December 31, 2018, Selecta Biosciences, Inc. had $37.4 million of cash and cash equivalents
We estimate that the net proceeds from this offering, after deducting underwriting discounts and commissions and estimated offering expenses payable by us, will be approximately $27.9 million or $32.1 million if the underwriters exercise their option to purchase additional shares of common stock in full.
Selecta verbrennt natürlich auch ein Haufen Kohle!
We incurred net losses of $50.7 million and $45.8 million for the nine months ended September 30, 2018 and 2017
Vermutlich werden sie in 2019 weiter Kapital benötigen und auch besorgen.
Weiter haben sie noch:
The number of shares of our common stock to be outstanding immediately after this offering is based on 22,471,776 shares of our common stock outstanding as of December 31, 2018 and excludes:
•4,103,979 shares of our common stock issuable upon the exercise of stock options outstanding as of December 31, 2018 at a weighted average exercise price of $9.20 per share;
•176,432 shares of common stock issuable upon exercise of warrants outstanding as of December 31, 2018, at a weighted average exercise price of $17.32 per share;
•175,000 shares of common stock issuable upon vesting of restricted stock units outstanding as of December 31, 2018;
•1,037,031 shares of common stock reserved for issuance under our 2016 Incentive Award Plan, or the 2016 Plan, as of December 31, 2018, as well as shares that become available pursuant to provisions in our 2016 Plan that automatically increase the share reserve under the 2016 Plan; and
•539,894 shares of common stock reserved for issuance under our 2016 Employee Stock Purchase Plan, or the 2016 ESPP, as of December 31, 2018, as well as shares that become available pursuant to provisions in our 2016 ESPP that automatically increase the share reserve under the 2016 ESPP.
Steht alles in den SEC Q3 und KE
https://www.nasdaq.com/symbol/selb/sec-filings
Um was geht es eigentlich beiSelecta?
Selecta besitzt als Hauptkandidat SEL-212, eine Suppe gegen Gicht, die in 2019 gegen das zugelassene Krystexxa getestet werden soll. Die Studie soll im Q1 beginnen, mit einem Zwischenbericht nach 6 Monaten und schlussendlich die finalen Daten im Q1 2020. Denke bei guten Daten mit dem großen Markt im Rücken ..............
Die finalen Phase2 Daten stehen momentan auch noch aus. Die Phase 3 soll im Q4 2019 starten.
The Company intends to use the net proceeds of the offering and a portion of its existing cash and cash equivalents to advance the clinical development of SEL-212, including the completion of a head-to-head superiority trial of SEL-212 compared to the current FDA-approved uricase therapy, completion of the Phase 2 clinical trial and preparations for a Phase 3 clinical trial, pursue other pre-clinical programs, including gene therapy development work, and for other operational activities and general corporate purposes.
http://secfilings.nasdaq.com/...=13168382&RcvdDate=1/24/2019&
On January 3, 2019, we announced new interim data from five patients in our Phase 2 trial of SEL-212 receiving five monthly combination doses of SEL-212, consisting of up to 0.15 mg/kg of ImmTOR in combination with 0.2 or 0.4 mg/kg of pegadricase. In these cohorts, approximately 66% of the evaluable patients maintained serum uric acid level control below 6 mg/dL throughout five months of therapy. Furthermore, reduced total urate burden and lowered flare rates and severity were observed in the Phase 2 clinical trial, and SEL-212 continued to be generally well tolerated.
In addition, we announced plans to initiate a head-to-head superiority trial of SEL-212, utilizing revised stopping rules, compared to the current FDA-approved uricase therapy, Krystexxa, in the first quarter of 2019. An interim six-month data readout is projected for the fourth quarter of 2019 with a full statistical superiority data analysis expected in the first quarter of 2020. We plan to initiate a Phase 3 clinical trial of SEL-212 in the fourth quarter of 2019.
CoName=SELECTA%20BIOSCIENCES%20INC&FormType=8-K&View=html
Aber bestand hat noch......................As of September 30, 2018 and December 31, 2017 , the outstanding principal balance under the 2017 Term Loan was $21.0 million
Future minimum principal and interest payments on the 2017 Term Loan as of September 30, 2018 are as follows (in thousands):
§
2018 (Remainder) $ 309
2019 4,690
2020 9,197
2021 8,705
2022 1,754
Total minimum debt payments $ 24,655
Less: Amount representing interest (2,605)
Less: Debt discount and deferred charges (751)
Less: Current portion of loan payable (21,299)
Zu lesen im Q3 2018
http://secfilings.nasdaq.com/...20INC&FormType=10-Q&View=html
Selecta hat am 10 August, 2017 auch noch ein ATM auf den Weg gebracht. Sie dürfen Aktien bis 50 Mio$ in den Markt verkaufen. Das at-the-market offering ist bis zum 30.9.2018 noch nicht in Anspruch genommen worden.
01.02.19 1,92 M mit Schlusskurs von 1,7$.
Finanziert bis in Q2 2020
The Company believes that the net proceeds from the offering and its existing cash resources as of December 31, 2018 will be sufficient to enable the Company to fund its operating expenses and capital expenditure requirements into the second quarter of 2020
https://selectabio.gcs-web.com/static-files/...488e-a7ff-c27cb199bea1
Vom 3.1.19
Mal zu Krystexxa.
The following table reflects net sales by medicine for the Company’s reportable segments for the three and nine months ended September 30, 2018 and 2017 (in thousands):
net sales
KRYSTEXXA
Three Months Ended September 30
2018 $70,246
2017 $42,752
Nine Months Ended September 30,
2018 $175,572
2017 $112,667
http://ir.horizon-pharma.com/static-files/...c-4999-96d8-ff8fb66f3cf4
Der Marktanteil für Krystexxa ist nicht gerade der größte, könnte aber an den Nebenwirkungen liegen.
Nächster Step. Werde die Medis durchleuchten!
today announced that it will report its fourth quarter full year end 2018 financial results and provide a corporate update before the open of the U.S. financial markets on Friday, March 15, 2019.
https://selectabio.gcs-web.com/news-releases/...ter-and-year-end-2018
Selecta Biosciences to Present at the Cowen Annual Health Care Conference March 13, 2019
https://selectabio.gcs-web.com/news-releases/...ealth-care-conference
Selecta Biosciences Is Worth A Look After Restructuring
https://seekingalpha.com/article/...sciences-worth-look-restructuring
--Phase 2 head-to-head (COMPARE) clinical trial of SEL-212 vs. KRYSTEXXA® to begin in 1Q19, interim six-month data expected in 4Q19
--Collaboration with CureCN projected to dose first patient with combination of ImmTOR + AAV gene therapy candidate in 2H19
--Company raises $33M in gross offering proceeds and $31.3M in net proceeds in 1Q19, cash runway into 1Q20
Die Interim Daten SEL-212 vs. KRYSTEXXA® sind schon mal finanziell abgedeckt
An interim six-month data readout is projected for the fourth quarter of 2019, with a full statistical data analysis expected in the first quarter of 2020
Ariva Selecta Hauptseite eingepflegt werden.
As of March 8, 2019 the registrant had 44,733,437 shares of common stock, par value $0.0001 per share, outstanding.
https://selectabio.gcs-web.com/static-files/1c42049a-f632-4a11-a359-949c668770da
Selecta Biosciences Initiates Head-to-Head Clinical Trial (COMPARE) of SEL-212 vs. KRYSTEXXA® in Patients with Chronic Refractory Gout and Strengthens Management Team
https://selectabio.gcs-web.com/news-releases/...linical-trial-compare
Selecta Biosciences to Announce Date of First Quarter 2019 Financial Results Conference Call
WATERTOWN, Mass., May 02, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR (SVP Rapamycin), today announced that it plans to issue its first quarter 2019 financial results before the open of the U.S. financial markets on Thursday, May 09, 2019.
https://selectabio.gcs-web.com/news-releases/...uarter-2019-financial
https://selectabio.com/investors&media/media
Projected upcoming milestones
-Guidance from FDA meeting regarding Phase 3 clinical development plan (Q1 2020)
-Report top-line data from SEL-212 vs. KRYSTEXXA® COMPARE trial in chronic refractory gout (mid 2020)
-Planning to commence clinical trial of ImmTORin gene therapy (2020)
und diesen Nachrichten, was an sich mMn positiv sind, heute eingestiegen
https://www.globenewswire.com/news-release/2020/...fractory-Gout.html